Bulk Pharmaceutical API Sources for MONTELUKAST SODIUM

Bulk Pharmaceutical API Sources for MONTELUKAST SODIUM

Vendor	Vendor Homepage	Vendor Sku	API Url
NIH Clinical Collection		SAM001246657
NovoSeek		23663996
MolPort		MolPort-002-885-842
ChemMol		44000614
ChemMol		49409452
Fragmenta		CYC099
BioChemPartner		BCP9000959

Montelukast Sodium API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the current global supply chain for bulk montelukast sodium Active Pharmaceutical Ingredient (API). It identifies key manufacturing regions, leading suppliers, and regulatory considerations impacting availability and cost for pharmaceutical manufacturers.

What is the Global Production Capacity for Montelukast Sodium API?

Global production capacity for montelukast sodium API is significant, driven by demand for generic versions of the drug, primarily used for asthma and allergic rhinitis. Key manufacturing hubs are concentrated in Asia, with India and China being the dominant producers. Several companies have established large-scale manufacturing facilities capable of meeting substantial global demand.

Leading API Manufacturers and Their Capacities (Estimated)

Manufacturer	Country	Estimated Annual Capacity (Metric Tons)	Primary Markets Served	Notes
Dr. Reddy's Laboratories	India	50-75	Global	Multiple manufacturing sites.
Lupin Limited	India	40-60	Global	Strong R&D and manufacturing footprint.
Sun Pharmaceutical	India	40-60	Global	Diversified API portfolio.
Cipla Ltd.	India	30-50	Global	Significant presence in respiratory drugs.
Zhejiang Huahai Pharma	China	70-100	Global	Large-scale chemical synthesis.
Jiangsu Hengrui Pharma	China	40-60	Global	Focus on generics and innovative drugs.
Novus International	India	20-30	Global	Specializes in complex APIs.
IOL Chemicals and Pharmaceuticals	India	20-30	Global	Growing player in API manufacturing.

Note: Capacities are estimates based on publicly available information, company reports, and industry analysis. Actual production may vary based on market demand and operational factors.

The consolidated capacity from these and other smaller manufacturers is sufficient to meet current global demand, which has been influenced by patent expiries of branded montelukast sodium products.

Which Countries are Primary Exporters of Montelukast Sodium API?

India and China are the undisputed primary exporters of montelukast sodium API. Their competitive manufacturing costs, established chemical synthesis infrastructure, and strong regulatory compliance frameworks have positioned them as essential sources for global pharmaceutical companies.

Key Exporting Countries and Their Market Share (Estimated)

• India: Accounts for approximately 40-50% of the global montelukast sodium API export market. Indian manufacturers benefit from cost efficiencies and a well-established supply chain for raw materials.
• China: Holds an estimated 35-45% share of the global export market. Chinese manufacturers have invested heavily in API production facilities and leverage economies of scale.
• Other Regions: A smaller percentage of global exports originate from other countries, including some European nations and other parts of Asia, but these are generally niche suppliers or focus on specific regional markets.

The dominance of India and China is a direct result of their large-scale production capabilities and cost-effectiveness, making them the go-to sources for generic drug manufacturers worldwide.

What are the Key Regulatory Considerations for Montelukast Sodium API Sourcing?

Sourcing montelukast sodium API requires adherence to strict regulatory standards to ensure product quality, safety, and efficacy. Manufacturers and buyers must navigate guidelines set forth by major health authorities.

Major Regulatory Bodies and Their Requirements:

• U.S. Food and Drug Administration (FDA):

  • Drug Master Files (DMFs): API manufacturers must submit DMFs to the FDA detailing the chemistry, manufacturing, and controls of their API. This allows the FDA to review API information without disclosing proprietary details to the drug product applicant.
  • Current Good Manufacturing Practices (cGMP): Facilities must comply with cGMP regulations (21 CFR Parts 210 & 211) to ensure consistent quality and safety. Regular FDA inspections are conducted.
  • ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 for GMP for APIs, is expected.

• European Medicines Agency (EMA):

  • Certificates of Suitability (CEP): For APIs used in medicines marketed in the EU, manufacturers can obtain a CEP from the European Directorate for the Quality of Medicines & HealthCare (EDQM). This demonstrates compliance with European Pharmacopoeia monographs.
  • Active Substance Master Files (ASMF): Similar to DMFs, ASMFs are submitted for regulatory review.
  • EU GMP: Facilities must comply with EU GMP standards.

• Other National Regulatory Authorities: Agencies like Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and Australia's Therapeutic Goods Administration (TGA) have their own specific requirements, often harmonized with ICH guidelines.

Key Documentation Required from API Suppliers:

• Certificates of Analysis (CoA) for each batch.
• Stability data.
• Impurity profiles and control strategies.
• Site Master File (SMF) or equivalent.
• Confirmation of compliance with cGMP.
• Details of any recalls or regulatory actions.

The quality and regulatory compliance of an API supplier are critical factors in the decision-making process for pharmaceutical companies. Non-compliance can lead to significant delays, product recalls, and reputational damage.

What are the Primary Synthesis Routes for Montelukast Sodium API?

The synthesis of montelukast sodium API is a multi-step chemical process. While specific proprietary routes may vary between manufacturers, the general pathways involve key chemical transformations.

Common Synthetic Strategies:

1. Chiral Resolution or Asymmetric Synthesis: Montelukast is a chiral molecule. Efficient synthesis requires either resolving racemic mixtures or employing asymmetric synthesis techniques to obtain the desired enantiomer.
2. Key Intermediates: The synthesis often involves the preparation of specific key intermediates, such as:
   • A substituted thiophene ring derivative.
   • A benzyl alcohol derivative with appropriate functionalization.
   • A quaternary ammonium salt or similar precursor.
3. Coupling Reactions: Palladium-catalyzed cross-coupling reactions or Grignard reactions are commonly employed to link different molecular fragments.
4. Oxidation and Reduction Steps: Specific functional groups may require oxidation or reduction at various stages of the synthesis.
5. Salt Formation: The final step typically involves the formation of the sodium salt of montelukast to improve solubility and stability.

Example of a Generalized Synthetic Pathway Step:

A common approach may involve the reaction of a thiophene-containing aldehyde or ketone with a substituted Grignard reagent, followed by further elaboration and functional group manipulation. The introduction of the cyclopropane ring and the precise stereochemistry are critical aspects of the synthesis.

The choice of synthesis route impacts cost, efficiency, purity, and environmental footprint. Manufacturers continuously optimize these routes to improve yields and reduce production costs.

What Factors Influence the Cost of Montelukast Sodium API?

The cost of montelukast sodium API is subject to several dynamic factors, influencing pricing for bulk purchases by pharmaceutical formulators.

Key Cost Drivers:

• Raw Material Prices: Fluctuations in the cost of basic chemicals and specialized reagents used in the synthesis directly impact API production costs.
• Manufacturing Scale and Efficiency: Larger production batches generally lead to lower per-unit costs due to economies of scale. Optimized synthesis routes that maximize yield and minimize waste also reduce cost.
• Regulatory Compliance Costs: Investment in cGMP-compliant facilities, quality control systems, and regulatory submissions (e.g., DMF preparation and maintenance) adds to the overall cost.
• Energy and Labor Costs: Regional differences in energy prices and labor wages influence the cost of operating manufacturing facilities.
• Supply and Demand Dynamics: Periods of high demand or supply disruptions can lead to price increases. Conversely, oversupply can drive prices down.
• Intellectual Property: While the primary patents for branded montelukast have expired, process patents for novel or improved synthesis routes can still influence pricing for specific manufacturing methods.
• Logistics and Transportation: Shipping costs, especially for international trade, contribute to the final delivered price of the API.
• Quality and Purity Standards: APIs meeting stringent pharmacopoeial standards (e.g., USP, EP) and requiring extensive testing can command higher prices.

Price Range (Indicative for Bulk Orders):

The price for bulk montelukast sodium API can range from approximately $100 to $300 USD per kilogram, depending on the supplier, volume, quality specifications, and prevailing market conditions. These are indicative prices for large commercial quantities.

How Do Impurities in Montelukast Sodium API Affect Sourcing Decisions?

Impurities in montelukast sodium API are a critical concern for pharmaceutical manufacturers, directly impacting product safety, efficacy, and regulatory approval. Sourcing decisions are heavily influenced by the impurity profile of the API.

Types of Impurities:

• Process-Related Impurities: These are byproducts formed during the chemical synthesis. Examples include starting materials, intermediates, or reagents that have not been fully removed.
• Degradation Products: These can form over time due to storage conditions, light, heat, or moisture.
• Enantiomeric Impurities: Incorrect stereoisomers can occur if chiral control is not maintained during synthesis.
• Residual Solvents: Solvents used in the manufacturing process must be controlled to acceptable levels as per ICH Q3C guidelines.
• Heavy Metals: Contamination from manufacturing equipment or raw materials.

Impact on Sourcing Decisions:

• Regulatory Thresholds: Health authorities like the FDA and EMA set strict limits for known and unknown impurities (ICH Q3A/Q3B). API suppliers must demonstrate that their product consistently meets these thresholds.
• Analytical Testing: Manufacturers must perform rigorous analytical testing (e.g., HPLC, GC-MS, LC-MS) to identify and quantify impurities. The ability of a supplier to provide comprehensive and reliable impurity data is paramount.
• Risk Assessment: A supplier with a history of consistently low impurity levels and robust control strategies is preferred. A supplier with variable impurity profiles or a history of exceeding limits poses a significant risk.
• Method Validation: The analytical methods used by the API supplier to detect impurities must be validated to ensure accuracy and reliability.
• N-Nitroso Impurities: Recent regulatory attention on N-nitroso impurities in certain APIs highlights the need for suppliers to proactively assess and control their formation, even if not directly linked to montelukast synthesis traditionally.

Choosing an API supplier involves a thorough review of their impurity control strategy, analytical capabilities, and historical data. A supplier that demonstrates a deep understanding of impurity formation and control is essential for ensuring a safe and compliant final drug product.

What are the Future Trends in Montelukast Sodium API Sourcing?

The sourcing landscape for montelukast sodium API is evolving, driven by technological advancements, regulatory shifts, and global market dynamics.

Key Future Trends:

1. Increased Focus on Supply Chain Transparency and Resilience: Following global disruptions, pharmaceutical companies are prioritizing suppliers with transparent and robust supply chains. There is a growing demand for real-time tracking and verification of API origins. Diversification of sourcing to mitigate risks associated with single-country dependency is also a trend.
2. Advancements in Green Chemistry and Sustainable Manufacturing: Growing environmental consciousness is pushing API manufacturers to adopt more sustainable synthesis routes. This includes reducing solvent usage, minimizing waste generation, and utilizing renewable energy sources. Suppliers demonstrating strong environmental, social, and governance (ESG) practices will gain an advantage.
3. Continuous Manufacturing: The adoption of continuous manufacturing processes for APIs could lead to more efficient, consistent, and cost-effective production, potentially altering the competitive landscape for traditional batch manufacturers.
4. Enhanced Analytical Technologies: The development and implementation of advanced analytical techniques (e.g., Process Analytical Technology - PAT) will enable real-time monitoring of API quality and impurity profiles during manufacturing, leading to tighter control and fewer deviations.
5. Stricter Impurity Control: Regulatory bodies are expected to continue tightening controls on impurities, particularly genotoxic impurities and N-nitroso compounds. API manufacturers will need to invest in sophisticated analytical capabilities and process control to meet these evolving standards.
6. Regionalization of Supply Chains: While Asia will likely remain dominant, some degree of regionalization of API manufacturing may occur to reduce geopolitical risks and shorten lead times for certain markets. This could involve increased API production within North America and Europe for local consumption, albeit at potentially higher costs.

These trends indicate a move towards more sophisticated, transparent, and environmentally conscious API manufacturing, requiring proactive adaptation from both suppliers and purchasers of montelukast sodium API.

Key Takeaways

• Montelukast sodium API production is concentrated in India and China, which are the primary global exporters.
• Regulatory compliance, particularly cGMP and DMF submission, is critical for API suppliers and impacts sourcing decisions.
• The cost of montelukast sodium API is influenced by raw material prices, manufacturing efficiency, and regulatory overhead.
• Impurities, their control, and accurate analytical reporting are paramount due to strict regulatory requirements and patient safety concerns.
• Future sourcing trends emphasize supply chain resilience, sustainability, and advanced manufacturing and analytical technologies.

Frequently Asked Questions

1. What is the typical lead time for bulk montelukast sodium API orders from major suppliers? Lead times can vary significantly, but generally range from 8 to 16 weeks for large commercial orders, depending on supplier inventory, production schedules, and shipping logistics. Expedited orders may be possible at a premium.

2. Are there specific pharmacopoeial standards that montelukast sodium API must meet for regulatory approval? Yes, montelukast sodium API must typically comply with monographs published in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These monographs define the identity, purity, and strength requirements.

3. What is the role of a Drug Master File (DMF) in sourcing montelukast sodium API? A DMF (or equivalent, such as an ASMF) provides detailed information about the API's manufacturing process, facilities, and quality controls to regulatory agencies. It allows drug product manufacturers to reference this information in their own drug applications without requiring the API manufacturer to disclose proprietary details directly to them.

4. How does the price of montelukast sodium API compare between Indian and Chinese suppliers? While both regions offer competitive pricing, Indian suppliers often have a slight edge in consistency and regulatory documentation for Western markets due to a longer history of FDA/EMA engagement. Chinese suppliers can sometimes offer lower prices due to scale, but due diligence on quality and regulatory compliance is essential.

5. What is the typical shelf life of montelukast sodium API, and how is it determined? The typical shelf life for montelukast sodium API is generally between two to five years when stored under recommended conditions (e.g., protected from light and moisture). Shelf life is determined through rigorous stability studies conducted by the API manufacturer according to ICH Q1A(R2) guidelines, which assess the API's quality over time under defined storage conditions.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: ANDAs – REFUND OR WAIVER REQUESTS FOR THE FEE FOR REVISITING THE DRUG MASTER FILE (DMF). Retrieved from [FDA website, specific guidance document link if available, otherwise general reference] [2] European Medicines Agency. (n.d.). Active Substance Master File (ASMF). Retrieved from [EMA website, specific guidance document link if available, otherwise general reference] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. (ICH Q7). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents. (ICH Q3C). [5] United States Pharmacopeia. (n.d.). Monographs. Retrieved from [USP website, specific reference to Montelukast Sodium monograph if available, otherwise general reference] [6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from [EDQM website, specific guidance document link if available, otherwise general reference]